# Phase II Study of Intravenous Rexin-G in Osteosarcoma

> **NCT00572130** · PHASE2 · COMPLETED · sponsor: **Epeius Biotechnologies** · enrollment: 22 (actual)

## Conditions studied

- Osteosarcoma

## Interventions

- **GENETIC:** Rexin-G Dose 1
- **GENETIC:** Rexin-G Dose 2

## Key facts

- **NCT ID:** NCT00572130
- **Lead sponsor:** Epeius Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-07
- **Final completion:** 2011-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2011-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00572130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00572130, "Phase II Study of Intravenous Rexin-G in Osteosarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00572130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*